Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9266
Title: Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
Authors: Cao, Zemin;Cooper, Mark E;Wu, L L;Cox, Allison J;Jandeleit-Dahm, K;Kelly, D J;Gilbert, Richard E
Affiliation: Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg West, Victoria, Australia
Issue Date: 1-Oct-2000
Citation: Hypertension; 36(4): 561-8
Abstract: The renin-angiotensin system (RAS) and endothelin system may both play a role in the pathogenesis of progressive renal injury. The aims of the present study were 3-fold: first, to explore the possible benefits of dual blockade of the RAS with an ACE inhibitor and an angiotensin type 1(AT1) receptor antagonist; second, to examine the relative efficacy of endothelin A receptor antagonism (ETA-RA) compared with combined endothelin A/B receptor antagonism (ETA/B-RA); and third, to assess whether interruption of both RAS and endothelin system had any advantages over single-system blockade. Subtotally nephrectomized rats were studied as a model of progressive renal injury and randomly assigned to one of the following treatments for 12 weeks: perindopril (ACE inhibitor), irbesartan (AT1 receptor antagonist), BMS193884 (ETA-RA), bosentan (ETA/B-RA), and a combination of irbesartan with either perindopril or BMS193884. Treatment with irbesartan or perindopril was associated with an improved glomerular filtration rate and reductions in blood pressure, urinary protein excretion, glomerulosclerosis, and tubular injury in association with reduced gene expression of transforming growth factor-beta(1) and matrix protein type IV collagen. The combination of irbesartan with perindopril was associated with further reductions in blood pressure and urinary protein excretion. No beneficial effects of either BMS193884 or bosentan were noted. Furthermore, the addition of BMS193884 to irbesartan did not confer any additional benefits. These findings suggest that the RAS but not the endothelin system is a major mediator of progressive renal injury after renal mass reduction and that the combination of an AT1 receptor antagonist with an ACE inhibitor may have advantages over the single agent of RAS blocker treatment.
Internal ID Number: 11040236
URI: http://ahro.austin.org.au/austinjspui/handle/1/9266
URL: http://www.ncbi.nlm.nih.gov/pubmed/11040236
Type: Journal Article
Subjects: Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors.administration & dosage
Animals
Antihypertensive Agents.administration & dosage
Blood Pressure.drug effects
Collagen.genetics.metabolism
Disease Models, Animal
Disease Progression
Drug Therapy, Combination
Endothelin Receptor Antagonists
Endothelin-1.metabolism
Glomerular Filtration Rate.drug effects
Kidney.drug effects.metabolism.pathology
Male
Nephrectomy
Proteinuria.urine
RNA, Messenger.metabolism
Rats
Rats, Sprague-Dawley
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Receptor, Endothelin A
Receptor, Endothelin B
Renal Insufficiency.drug therapy.metabolism
Renin-Angiotensin System.drug effects
Severity of Illness Index
Transforming Growth Factor beta.genetics.metabolism
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.